DcR3 regulates the growth and metastatic potential of SW480 colon cancer cells

Oncol Rep. 2013 Dec;30(6):2741-8. doi: 10.3892/or.2013.2769. Epub 2013 Oct 1.

Abstract

Decoy receptor 3 (DcR3) is considered to have anti‑apoptotic and pro-metastatic functions, suggesting it might be a therapeutic target. We examined the role and mechanisms of DcR3 on growth and the metastatic ability of SW480 colon cancer cells to provide therapeutic information for targeting DcR3 by RNA interference (RNAi) technology. Growth and the metastatic ability were inhibited, apoptosis was induced and cell cycle profile was changed after decreasing DcR3 expression, with lower levels of vascular endothelial growth factors (VEGFs) and matrix metalloproteinases (MMPs) expression. Our results implied the therapeutic potential of silencing DcR3 expression by RNAi in colon cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apoptosis / genetics*
  • Cell Line, Tumor
  • Colonic Neoplasms / genetics*
  • Colonic Neoplasms / pathology
  • Gene Expression Regulation, Neoplastic*
  • Humans
  • Matrix Metalloproteinases / biosynthesis
  • Neoplasm Metastasis / genetics
  • Neoplasm Metastasis / pathology
  • RNA Interference
  • Receptors, Tumor Necrosis Factor, Member 6b / biosynthesis
  • Receptors, Tumor Necrosis Factor, Member 6b / genetics*
  • Vascular Endothelial Growth Factors / biosynthesis

Substances

  • Receptors, Tumor Necrosis Factor, Member 6b
  • TNFRSF6B protein, human
  • Vascular Endothelial Growth Factors
  • Matrix Metalloproteinases